Search
L-lysyl-l-arginine
go.drugbank.com/drugs/DB19436InvestigationalL-lysyl-l-arginine is under investigation in clinical trial NCT03972488 (Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET).
Xeruborbactam
go.drugbank.com/drugs/DB21512InvestigationalThe usage of the INN stem '-bactam' in the name indicates that Xeruborbactam is a ẞ-lactamase inhibitor. … Xeruborbactam is under investigation in clinical trial NCT07104162 (A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal Impairment).
Iboctadekin
go.drugbank.com/drugs/DB14920InvestigationalIboctadekin is under investigation in clinical trial NCT00500058 (A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18).
PL-3994
go.drugbank.com/drugs/DB15355InvestigationalPL-3994 is under investigation in clinical trial NCT01304628 (Cross-Over Study of Subcutaneous Study Drug for the Treatment of Patients With Mild to Moderate Asthma).
Omzotirome
go.drugbank.com/drugs/DB16046InvestigationalTRC150094 is under investigation in clinical trial NCT03254446 (Safety and Efficacy Study of TRC150094 to Improve the CV Risk in Subjects With Diabetes, Dyslipidemia and Hypertension).
Burfiralimab
go.drugbank.com/drugs/DB18935InvestigationalBurfiralimab is under investigation in clinical trial NCT06306339 (A Study to Assess the Efficacy and Safety of Burfiralimab (Hzvsf-v13) and DMRD (Disease-modifying Antirheumatic Drug)).
ABT-341
go.drugbank.com/drugs/DB08044ExperimentalABT-341 is a potent and selective DPP-4 inhibitor with a structure very similar to sitagliptin (in 2D; the 3D structure is significantly different). [A39406]
Digoxigenin
go.drugbank.com/drugs/DB03671ExperimentalDigoxigenin is a cardenolide which is the aglycon of digoxin. Can be obtained by hydrolysis of digoxin or from Digitalis orientalis L. and Digitalis lanata Ehrh.
Osanetant
go.drugbank.com/drugs/DB04872InvestigationalDeveloped by Sanofi-Aventis (formerly Sanofi-Synthelabo), osanetant (SR-142801) is an NK3 receptor antagonist which was under development for the treatment of schizophrenia and other Central Nervous System … This follows an earlier decision to discontinue development of eplivanserin for schizophrenia.
BMS-986020
go.drugbank.com/drugs/DB14948InvestigationalBMS-986020 is under investigation in clinical trial NCT02017730 (To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding in Lung Using PET (Positron Emission Tomography) In Healthy